_ _    _ _____  ___   __                       
 __      _(_) | _(_)___ / ( _ ) / /_   ___ ___  _ __ ___  
 \ \ /\ / / | |/ / | |_ \ / _ \| '_ \ / __/ _ \| '_ ` _ \ 
  \ V  V /| |   <| |___) | (_) | (_) | (_| (_) | | | | | |
   \_/\_/ |_|_|\_\_|____/ \___/ \___(_)___\___/|_| |_| |_|

Suproclone

Today, Suproclone is a topic of great interest and relevance in society. Whether due to its impact on people's daily lives, its relevance in academia or its influence on technological development, Suproclone has managed to capture the attention of experts and fans alike. As we delve into this article, we will explore the different facets of Suproclone, its implications in today's society, and its potential for the future. From its origins to its contemporary evolution, Suproclone has proven to be a topic worthy of analysis and reflection, and this article aims to examine it carefully to understand its importance and relevance today.
Suproclone
Clinical data
ATC code
  • none
Identifiers
  • dithiinopyrrol-7-yl] 4-propanoylpiperazine-1-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.071.330 Edit this at Wikidata
Chemical and physical data
FormulaC22H22ClN5O4S2
Molar mass520.02 g·mol−1
3D model (JSmol)
  • O=C(N5CCN(C(=O)OC4C=1SCCSC=1C(=O)N4c2nc3nc(Cl)ccc3cc2)CC5)CC
  • InChI=1S/C22H22ClN5O4S2/c1-2-16(29)26-7-9-27(10-8-26)22(31)32-21-18-17(33-11-12-34-18)20(30)28(21)15-6-4-13-3-5-14(23)24-19(13)25-15/h3-6,21H,2,7-12H2,1H3 checkY
  • Key:IBAUKGNDWVSETP-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Suproclone is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs, developed by the French pharmaceutical company Rhône-Poulenc. Other cyclopyrrolone drugs include zopiclone, pagoclone and suriclone.

Suproclone is very similar in structure to the related drug suriclone, but little information has been published about it specifically. However it can be expected that the mechanism of action by which suproclone produces its sedative and anxiolytic effects is by modulating benzodiazepine receptors (resulting in an increased response to endogenous GABA), in a similar manner to other drugs of this class.

Synthesis

ChemDrug Synthesis: Patent (Ex 1/15):

The condensation between 2,3-Dihydro-1,4-dithiinofuran-5,7-dione (1) and 7-Chloro-1,8-naphthyridin-2-amine (2) gives PC23343647 (3). Halogenation with phosphoryl chloride leads to PC23343652 (4). Reductino with potassium borohydride afforded (5). Treatment with phenyl chloroformate (6) resulted in 2-(7-chloro-1,8-naphthyridin-2-yl)-3-phenoxycarbonyloxy-isoindolin-1-one, PC23343637 (7). Reaction with piperazine (8) afforded (9). Acylation with propionyl chloride completed the synthesis of Suproclone (10).

References

  1. ^ Psychotropics.dk. "suproclone". Retrieved 24 August 2009.
  2. ^ Gardner CR (1988). "Pharmacological profiles in vivo of benzodiazepine receptor ligands". Drug Development Research. 12 (1): 1–28. doi:10.1002/ddr.430120102. S2CID 85573551.
  3. ^ Doble A, Martin I, Nutt D (23 October 2003). Calming the brain: benzodiazepines and related drugs from laboratory to clinic. Informa Healthcare. ISBN 1-84184-052-1.
  4. ^ Serradell, MN; Castaer, J.; Suproclone. Drugs Fut 1985, 10, 1, 45.
  5. ^ Claude Cotrel, Claude Jeanmart, Mayer N. Messer, Cornel Crisan, U.S. patent 4,220,646 (1980 to Rhone-Poulenc Industries).
Stub icon

This sedative-related article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia